Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Summary

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Carcinoma, Renal Cell
• Advanced Renal Cell Carcinoma
• Renal Cancer
• Renal Neoplasm
• Clear Cell Renal Cell Carcinoma
• Metastatic Renal Cell Carcinoma
• Clear-cell Metastatic Renal Cell Carcinoma
• Carcinoma, Renal Cell Metastasis
• Advanced or Metastatic Renal Cell Carcinoma
• Carcinoma, Renal Cell, Advanced
• Metastatic Renal Cell Cancer
• Metastatic Renal Cell Carcinoma ( mRCC)
• Metastatic/Advanced Renal Cell Carcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites